Pharmaceutical products

Tender description

NHS National Pharmaceuticals Transition 2019_2 Offer reference number: CM/PHG/17/5548 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months Potential periods of call-offs under the framework agreement: NWLN: 1 February 2020 to 30 September 2020 (8 months) LSNE: 1 February 2020 to 28 February 2021 (13 months) CESW: 1 February 2020 to 31 October 2021 (21 months). Products on the framework include (but are not limited to): Azacitadine Colesevelam hcl Deferiprone Ezetimibe + simvastatin Fosamprenavir calcium Lopinavir + ritonavir Oxybutinin patches Parecoxib Posaconazole Roflumilast Sodium oxybate Vildagliptin + metformin Vinflunine ditartrate Vinorelbine (oral). NHS National Pharmaceuticals Transition 2019_2 Offer reference number: CM/PHG/17/5548 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 42 months potential periods of call-offs under the framework agreement: NWLN: 1 February 2020 to 30 September 2020 (8 months) LSNE: 1 February 2020 to 28 February 2021 (13 months) CESW: 1 February 2020 to 31 October 2021 (21 months). NHS National Pharmaceuticals Transition 2019_2 Offer reference number: CM/PHG/17/5548 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 42 months potential periods of call-offs under the framework agreement: NWLN: 1 February 2020 to 30 September 2020 (8 months) LSNE: 1 February 2020 to 28 February 2021 (13 months) CESW: 1 February 2020 to 31 October 2021 (21 months). NHS National Pharmaceuticals Transition 2019_2 Offer reference number: CM/PHG/17/5548 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 42 months potential periods of call-offs under the framework agreement: NWLN: 1 February 2020 to 30 September 2020 (8 months) LSNE: 1 February 2020 to 28 February 2021 (13 months) CESW: 1 February 2020 to 31 October 2021 (21 months).